The ATH CVE deal pays C$12.00 per Athabasca share in cash or 0.264 of a Cenovus share, prorated so the total mix lands at 65% to 75% cash; at the October 16, 2026 close that blend was worth C$12.08 to C$12.11, slightly below Athabasca's C$12.15. In plain terms, the spread is negative. Holders who pick the stock option and get it in full would have held C$12.32 of Cenovus stock per share at that close. But proration decides how much of that option anyone gets, and that is why the headline price and the trading price don't match.

Our first take on the Cenovus-Athabasca arbitrage ran before the terms were parsed. Here they are, with the arithmetic shown.

The terms, per Athabasca share

Cenovus Energy ($CVE, TSX/NYSE: CVE) announced the deal on October 5, 2026, before the market opened. Its conference call was at 9 a.m. ET, ahead of the 9:30 a.m. open. According to Cenovus's release, each Athabasca (TSX: ATH) holder can elect one of three options per share:

• C$12.00 in cash;
• 0.264 of a Cenovus common share; or
• a mix of the two.

Anyone who doesn't make a valid election is deemed to have elected cash. All elections are prorated against two caps: a maximum of C$4.3 billion in cash (75% of the total consideration) and a maximum of 44.4 million Cenovus shares (35%). The aggregate result is therefore between 65% and 75% cash.

Athabasca's release puts the equity value at about C$5.8 billion and says C$12.00 is a 14% premium to its 20-day volume-weighted average price. Cenovus cites an implied enterprise value of C$5.7 billion. The lower enterprise value is consistent with Athabasca holding more cash than debt: FMP data shows net cash of about C$86 million at June 30, 2026.

Premium check: 13.4% on the last close

Athabasca closed at C$10.58 on October 2, 2026, the last session before the announcement. Against that close, C$12.00 is a 13.4% premium (12.00 ÷ 10.58 − 1). As a rough cross-check of the 14% VWAP premium in the release, we weighted the 20 FMP daily closes from September 4 to October 2, 2026 by volume. That gives C$10.54 and a 13.9% premium. This is an approximation, not the official intraday VWAP.

On October 5, 2026, ATH.TO closed at C$12.01 on 20,446,400 shares, against 2,209,300 shares traded on October 2. The deal was priced in on day one.

The spread at the October 16, 2026 close

Inputs: ATH.TO C$12.15, CVE.TO C$46.67. Per Athabasca share, value = cash share × C$12.00 + stock share × 0.264 × CVE.TO.

The breakeven is CVE.TO at C$45.45 (12.00 ÷ 0.264). Above that price, the stock leg is worth more than cash. Below it, cash is worth more. At the October 16, 2026 close, Cenovus was C$1.22 above breakeven, so the stock election was the better one.

This has held since the announcement. Athabasca traded above the blended value at every close from October 5 to October 16, 2026. The gap was widest at the October 7 close, when ATH.TO was C$12.27 against a blend of C$11.84 to C$11.88 with CVE.TO at C$43.67.

Annualizing it: only the best case is positive

Cenovus says it expects closing in December 2026. Assume December 15, which is 60 days after October 16. A simple annualized return is the spread % × 365 ÷ days.

• All-stock outcome: 1.41% × 365 ÷ 60 = about 8.6% annualized. If closing slips to December 31 (76 days), it is about 6.8%.
• Either blended outcome: negative, so there is nothing to annualize. A buyer at C$12.15 would get less than they paid if the blend applied and CVE.TO stayed at C$46.67.

Those figures leave out commissions, borrowing costs, the risk of the deal breaking and any dividend differences. They also assume the stock election gets fully filled, which nobody can promise. Non-electors default to cash, which leaves more room under the 44.4 million share cap for holders who actively elect stock. How much room depends on what everyone else elects.

What CVE moves do to the value

The exchange ratio is fixed, and neither release describes a collar. The value of every Athabasca share therefore moves with Cenovus, but proration limits how much.

Even an all-cash election carries Cenovus risk. If CVE.TO trades below C$45.45, cash is the better election. If enough holders choose it, cash hits its 75% cap, and every cash elector is prorated into at least 25% stock. With CVE.TO down 10%, that floor blend works out to C$11.77, 3.1% below the October 16, 2026 ATH.TO close.

For cross-listed context, $CVE closed at US$32.94 on the NYSE on October 16, 2026.

What the spread is pricing

• Time: the release targets December 2026. The shareholder meeting is expected in late November 2026, followed by a final order from the Court of King's Bench of Alberta.
• Approvals: Competition Act (Canada) and stock exchange approvals. The details are in our ATH CVE deal vote and timeline guide.
• The vote: directors and officers holding about 2.2% of the shares signed support agreements. That is a small locked-up block.
• Cenovus price risk: as the table shows, at least 25% of the consideration is stock, whatever anyone elects.
• Optionality: a price above the blend suggests traders are paying for the chance of a fuller stock fill. Some may also be paying for the hope of better terms, which neither company has signalled.

For the sector backdrop, see the week’s top TSX resource movers, and more deal coverage under Markets.

FAQ

What is the ATH CVE deal price?

C$12.00 cash or 0.264 of a Cenovus share for each Athabasca share, or a mix. Proration keeps the total at 65% to 75% cash. The deal was announced October 5, 2026.

Is the spread positive?

Only in the all-stock case. At the October 16, 2026 close, the blended value was C$12.08 to C$12.11 and ATH.TO was C$12.15. A fully filled stock election was worth C$12.32.

At what Cenovus price are cash and stock equal?

C$45.45 on the TSX (12.00 ÷ 0.264). CVE.TO closed at C$46.67 on October 16, 2026.

Can I guarantee all cash?

No. If cash elections exceed the C$4.3 billion cap, cash electors are prorated and receive some Cenovus shares.